Psychological status of elderly patients suffering arterial hypertension in metabolic syndrome against the background of chronotherapy

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Arterial hypertension in the metabolic syndrome in the elderly contributes to the formation of cognitive disorders and anxiety-depressive disorders. It is shown that the severity of these deviations of the psychological continuum significantly decreases after 1 year, under the influence of an antihypertensive fixed combination of amlodipine, mesinopril and rosuvastatin in the chronotherapy mode (evening reception), than in the traditional application (morning reception in the equivalent dosage of 5/10/10 mg per day in both cases. The dynamics of cognitive impairment in chronotherapeutical approach in patients 60–74 flights from arterial hypertension with metabolic syndrome is characterized by a significant increase in the average score on a scale MMSE, f source 17.8 ± 0.3 to 23.5 ± 0.4 points (р < 0.001), against 16.9 ± 0.3 to 20.4 ± 0.4 points (р < 0.001) in the morning taking the drug. Situational anxiety decreased from 40.8 ± 2.2 to 30.6 ± 1.8 points (р > 0.05) and from 40.0 ± 2.5 to 32.1 ± 2.0 points (р > 0.05), personal anxiety from 48.8 ± 2.0 to 25.4 ± 1.9 (р < 0.001) and from 44.9 ± 1.9 to 30.7 ± 1.7 (р < 0.01) points in the evening and morning the reception, respectively. Depressive disorders decreased slightly more significantly in chronotherapy (14.1% vs. 7.7%) than in the traditional scheme, but despite this, both cases with (groups) corresponded to depressive spectrum disorders. The results obtained indicate that chronotherapy is more effective than the traditional use of a fixed combination of amlodipine, lisinopril and rosuvastatin in arterial hypertension with metabolic syndrome.

作者简介

Nikolai Agarkov

Southwestern State University; Belgorod State National Research University

编辑信件的主要联系方式.
Email: vitalaxen@mail.ru

doctor of medical sciences, professor of the department of biomedical engineering, Southwestern State Donation University

俄罗斯联邦, Kursk; Belgorod

Oleg Okhotnikov

Kursk State Medical University

Email: vitalaxen@mail.ru

doctor of medical sciences, professor

俄罗斯联邦, Kursk

Snezhana Korneeva

Kursk State Medical University

Email: mitikhina2@mail.ru

candidate of medical sciences

俄罗斯联邦, Kursk

Ekaterina Moskaleva

Belgorod State National Research University

Email: vitalaxen@mail.ru

student

俄罗斯联邦, Belgorod

Alexander Moskalev

Belgorod State National Research University

Email: anton-titov-2001@mail.ru

student

俄罗斯联邦, Belgorod

Vsevolod Kolomyets

Kursk State Medical University

Email: kurskmed@mail.ru

resident

俄罗斯联邦, Kursk

Alexandra Markelova

Information and Methodological Center for Examination, Accounting and Analysis of Means of Medical Use

Email: markela@yandex.ru

an employee

俄罗斯联邦, Kursk

参考

  1. Sergeeva VA. Principles of antihypertensive therapy in metabolic syndrome. Klinicheskaya medicina. 2013;91(6):4–8. (In Russ.).
  2. Zhang J, Liu N, Yang Ch. Effects of rosuvastatin in comdination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease. Panminerra Med. 2019;61(4):439–443. doi: 10.23736/S0031-0808.18.03475-4
  3. Toshima T. Risk factors for the metabolic syndrome components of hypertension, diabetes mellitus, and dyslipidemia after living donor liver transplantation. HPB (Oxford). 2019;1365(182):30695–30701. doi: 10.1016/j.hpb.2019.08.008
  4. Satybaldieva AD. Features of the course of essential arterial hypertension in the elderly and senile age. Vestnik Almatinskogo gosudarstvennogo instituta usovershenstvovaniya vrachej. 2017;1:22–28. (In Russ.).
  5. Kryukov EV, Potekhin NP, Fursov AN, et al. Hypertensive crisis: modern view of the problem and optimization of diagnostic and therapeutic modalities. Clinical Medicine (Russian Journal). 2016;94(1):52–56. (In Russ.).
  6. Zhang J, Wang WL. Risk factors of metabolic syndrome after liver transplantation. Hepatobiliary Pancreat Dis Int. 2015;14(6):582–587. doi: 10.1016/S1499-3872(15)60037-6
  7. Ascaso JF. Prevalence of metabolic syndrome and cardiovascular disease in a hypertriglyceridemic population. Eur J Intern Med. 2011;22(2):177–181. doi: 10.1016/j.ejim.2010.12.011
  8. Gasparyan AYu. Features of metabolic syndrome in elderly and senile people, residents of besieged Leningrad. Sistemnye gipertenzii. 2008;5;263–269. (In Russ.).
  9. Dzherieva IS. Association between depression and metabolic syndrome. Klinicheskaya medicina. 2015;93(1):62–65. (In Russ.).
  10. Mikhailovskaya NS. Relationship of anxiety and depressive disorders with the course of coronary heart disease, comorbid with metabolic syndrome. Zaporozhskij medicinskij zhurnal. 2015;5:23–27. (In Russ.).
  11. Ostroumova OD. Effect of drugs with anticholinergic activity on the cognitive functions of patients 80 years and older with essential arterial hypertension. Arterial'naya gipertenziya. 2019;25(3):246–257. (In Russ.).
  12. Ibrahim MS. Risk models and scores for metabolic syndrome: systematic review protocol. BMJ OPEN. 2019;9(9):e027326. doi: 10.1136/bmjopen-2018-027326
  13. Rekomendacii ekspertov Vserossijskogo nauchnogo obshchestva kardiologov po diagnostike i lecheniyu metabolicheskogo sindroma (vtoroj peresmotr). Prakticheskaya medicina. 2010;44(5):81–101. (In Russ.).
  14. Nacional'nye rekomendacii ekspertov Vserossijskogo nauchnogo obshchestva kardiologov po diagnostike i lecheniyu arterial'noj gipertenzii (4-j peresmotr). Sistemnye gipertenzii. 2010;3:5–26. (In Russ.).
  15. Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6
  16. Khanin YuL. Research on anxiety in sports. Voprosy psihologii. 1978;6:92–99. (In Russ.).
  17. Andryushchenko AV, Drobizhev MYu, Dobrovolsky AV. Comparative evaluation of the CES–D, BDI and HADS(D) scale in the diagnosis of depression in General medical practice. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2003;5:11–18. (In Russ.).
  18. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053

补充文件

附件文件
动作
1. JATS XML

版权所有 © Agarkov N.M., Okhotnikov O.I., Korneeva S.I., Moskaleva E.O., Moskalev A.A., Kolomyets V.I., Markelova A.M., 2021

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。

##common.cookie##